CL2019001988A1 - Compuestos químicos como inhibidores de actividad interleuquina-2. - Google Patents
Compuestos químicos como inhibidores de actividad interleuquina-2.Info
- Publication number
- CL2019001988A1 CL2019001988A1 CL2019001988A CL2019001988A CL2019001988A1 CL 2019001988 A1 CL2019001988 A1 CL 2019001988A1 CL 2019001988 A CL2019001988 A CL 2019001988A CL 2019001988 A CL2019001988 A CL 2019001988A CL 2019001988 A1 CL2019001988 A1 CL 2019001988A1
- Authority
- CL
- Chile
- Prior art keywords
- opalis
- compounds
- modulation
- group
- substitute
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LA PRESENTE DESCRIPCIÓN PROVEE COMPUESTOS QUE SON EFICACES EN LA INHIBICIÓN DE UN INFLAMASOMA, TAL COMO EL INFLAMASOMA NLRP3. LOS COMPUESTOS TAMBIÉN SON EFICACES EN LA MODULACIÓN DE INTERLEUQUINAS. LOS COMPUESTOS DIVULGADOS TIENEN PESOS MOLECULARES, PROPIEDADES FISICOQUÍMICAS, Y LIPOFILICIDAD DESEABLES, LAS CUALES SON CARACTERÍSTICAS QUE AYUDAN A CONSEGUIR EFICACIA TERAPÉUTICA Y DISMINUIR LOS EFECTOS NO DESEADOS. LA PRESENTE INVENCIÓN PROVEE COMPUESTOS DE FÓRMULA I, Y SALES, FÁRMACOS, SOLVATOS, HIDRATOS, ISÓMEROS, O TAUTÓMEROS FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE: R1 SE SELECCIONA ENTRE EL GRUPO QUE CONSISTE EN C1-C6ALQUILO OPCIONALMENTE SUSTITUIDO, C1- C6ALQUENILO OPCIONALMENTE SUSTITUIDO, C1-C6ALQUINILO OPCIONALMENTE SUSTITUIDO, -(CH2)M-O- (CH2)M-CH3. LA PRESENTE DESCRIPCIÓN SE RELACIONA CON COMPUESTOS NOVEDOSOS DE SULFONILUREA Y SULFONIL TIOUREA COMPUESTOS Y COMPUESTOS RELACIONADOS Y SU USO PARA TRATAR UNA ENFERMEDAD O CONDICIÓN QUE ES SENSIBLE A LA MODULACIÓN DE CITOQUINAS TALES COMO IL-1Β E IL-18, MODULACIÓN DE NLRP3 O INHIBICIÓN DE LA ACTIVACIÓN DE NLRP3 O COMPONENTES RELACIONADOS DEL PROCESO INFLAMATORIO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762449431P | 2017-01-23 | 2017-01-23 | |
US201762492813P | 2017-05-01 | 2017-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001988A1 true CL2019001988A1 (es) | 2019-11-29 |
Family
ID=61189525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001988A CL2019001988A1 (es) | 2017-01-23 | 2019-07-15 | Compuestos químicos como inhibidores de actividad interleuquina-2. |
Country Status (21)
Country | Link |
---|---|
US (3) | US11040985B2 (es) |
EP (2) | EP3571187B1 (es) |
JP (1) | JP7163293B2 (es) |
KR (1) | KR20190111068A (es) |
CN (1) | CN110366549A (es) |
AU (1) | AU2018210525B2 (es) |
BR (1) | BR112019014549A2 (es) |
CA (1) | CA3047336A1 (es) |
CL (1) | CL2019001988A1 (es) |
CO (1) | CO2019009036A2 (es) |
CR (1) | CR20190356A (es) |
IL (1) | IL267961B2 (es) |
MA (2) | MA55695A (es) |
MX (1) | MX2019008592A (es) |
MY (1) | MY197636A (es) |
PE (1) | PE20191615A1 (es) |
PH (1) | PH12019501611A1 (es) |
SG (1) | SG11201906373VA (es) |
TW (1) | TW201837021A (es) |
UA (1) | UA126675C2 (es) |
WO (1) | WO2018136890A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
WO2019008025A1 (en) * | 2017-07-07 | 2019-01-10 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
US11203579B2 (en) | 2017-07-24 | 2021-12-21 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
EP3668862A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
UY37848A (es) * | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
SG11202003984UA (en) * | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
WO2019166619A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
US20200407340A1 (en) | 2018-03-02 | 2020-12-31 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
CN112533913A (zh) | 2018-05-04 | 2021-03-19 | 英夫拉索姆有限公司 | 新颖化合物 |
PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
CA3105521A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
AU2019322546A1 (en) | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
GB201817038D0 (en) * | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
EP3870168A1 (en) * | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
EP3870565A1 (en) | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
EP3911631A4 (en) | 2019-01-14 | 2022-09-28 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
CN113195469A (zh) * | 2019-02-19 | 2021-07-30 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
WO2021009566A1 (en) * | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
JP2022541514A (ja) * | 2019-07-17 | 2022-09-26 | ズーマゲン バイオサイエンシーズ エルティーディー | Nlrp3モジュレーター |
JP2022545400A (ja) | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Nlrp3阻害剤として有用な大環状スルホニル尿素誘導体 |
JP2022547882A (ja) | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Nlrp3阻害剤 |
AU2020383646B2 (en) * | 2019-11-12 | 2023-10-12 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Amide derivative and preparation method therefore and use thereof in medicine |
CN115362152A (zh) | 2020-02-18 | 2022-11-18 | 英夫拉索姆有限公司 | 化合物 |
WO2021188450A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
CA3178361A1 (en) | 2020-06-19 | 2021-12-23 | Emanuele Gabellieri | Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway |
CN114516878B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
TW202333678A (zh) * | 2021-12-22 | 2023-09-01 | 大陸商瑞石生物醫藥有限公司 | 一種磺醯脲類化合物 |
WO2023211929A1 (en) * | 2022-04-25 | 2023-11-02 | Vanderbilt University | Probes and methods for targeted visualization of nlrp3 inflammasomes |
WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
WO1998032733A1 (en) | 1997-01-29 | 1998-07-30 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
EP1487457A1 (en) | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
ES2600355T3 (es) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
KR20140075698A (ko) * | 2011-09-02 | 2014-06-19 | 교와 핫꼬 기린 가부시키가이샤 | 케모카인 수용체 활성 조절제 |
JP2016522831A (ja) * | 2013-05-21 | 2016-08-04 | ヴァージニア コモンウェルス ユニバーシティ | 炎症を予防および治療するためのクリオピリン阻害剤 |
EP3578547B1 (en) | 2015-02-16 | 2021-05-26 | The University of Queensland | Sulfonylureas and related compounds and use of same |
FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
SG11201806745RA (en) | 2016-02-16 | 2018-09-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
WO2017184624A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
WO2019008025A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
US20200361895A1 (en) | 2017-08-15 | 2020-11-19 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
WO2019043610A1 (en) * | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
SG11202003984UA (en) | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
US20200354341A1 (en) | 2017-11-09 | 2020-11-12 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
AU2019322546A1 (en) | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
EP3870565A1 (en) | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
-
2018
- 2018-01-22 CA CA3047336A patent/CA3047336A1/en active Pending
- 2018-01-22 MA MA055695A patent/MA55695A/fr unknown
- 2018-01-22 MA MA047308A patent/MA47308A/fr unknown
- 2018-01-22 MX MX2019008592A patent/MX2019008592A/es unknown
- 2018-01-22 CN CN201880014694.0A patent/CN110366549A/zh active Pending
- 2018-01-22 EP EP18704341.9A patent/EP3571187B1/en active Active
- 2018-01-22 AU AU2018210525A patent/AU2018210525B2/en active Active
- 2018-01-22 MY MYPI2019004010A patent/MY197636A/en unknown
- 2018-01-22 PE PE2019001474A patent/PE20191615A1/es unknown
- 2018-01-22 BR BR112019014549-4A patent/BR112019014549A2/pt active Search and Examination
- 2018-01-22 JP JP2019539814A patent/JP7163293B2/ja active Active
- 2018-01-22 CR CR20190356A patent/CR20190356A/es unknown
- 2018-01-22 KR KR1020197024262A patent/KR20190111068A/ko active IP Right Grant
- 2018-01-22 TW TW107102246A patent/TW201837021A/zh unknown
- 2018-01-22 UA UAA201907805A patent/UA126675C2/uk unknown
- 2018-01-22 WO PCT/US2018/014728 patent/WO2018136890A1/en active Application Filing
- 2018-01-22 SG SG11201906373VA patent/SG11201906373VA/en unknown
- 2018-01-22 EP EP20212018.4A patent/EP3851434A1/en active Pending
-
2019
- 2019-07-09 PH PH12019501611A patent/PH12019501611A1/en unknown
- 2019-07-10 IL IL267961A patent/IL267961B2/en unknown
- 2019-07-15 CL CL2019001988A patent/CL2019001988A1/es unknown
- 2019-07-16 US US16/513,621 patent/US11040985B2/en active Active
- 2019-08-21 CO CONC2019/0009036A patent/CO2019009036A2/es unknown
-
2021
- 2021-01-25 US US17/157,749 patent/US20210395268A1/en not_active Abandoned
-
2022
- 2022-03-03 US US17/686,183 patent/US11702428B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
ECSP20040257A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
ECSP18083519A (es) | Inhibidores de bromodominios | |
CO2020010465A2 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
CL2020002943A1 (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 | |
UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
CL2023001738A1 (es) | Inhibidores de prmt5 | |
ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
NI201500120A (es) | Compuestos de biaril - amida como inhibidores de cinasa | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
GT200600045A (es) | Derivados de piridizina y su uso como agentes terapeuticos | |
CO2019009722A2 (es) | Dendrímeros terapéuticos | |
CO2023007504A2 (es) | Derivados de carboxamida tricíclica como inhibidores de prmt5 | |
PE20210044A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
UY28993A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.- | |
UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas |